CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 277 filers reported holding CLOVIS ONCOLOGY INC in Q2 2017. The put-call ratio across all filers is 0.51 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $13,023,000 | -22.3% | 443,397 | +20.3% | 1.38% | -26.2% |
| Q2 2018 | $16,765,000 | -1.0% | 368,699 | +14.9% | 1.87% | +0.9% |
| Q1 2018 | $16,938,000 | +36.4% | 320,799 | +75.7% | 1.86% | +19.7% |
| Q4 2017 | $12,417,000 | -40.1% | 182,600 | -27.5% | 1.55% | -41.9% |
| Q3 2017 | $20,740,000 | +594.3% | 251,699 | +689.0% | 2.67% | +717.1% |
| Q2 2017 | $2,987,000 | -86.2% | 31,900 | -87.1% | 0.33% | -63.9% |
| Q2 2015 | $21,702,000 | +17.3% | 246,952 | -0.9% | 0.90% | +28.9% |
| Q1 2015 | $18,495,000 | -22.0% | 249,152 | -41.2% | 0.70% | -34.0% |
| Q4 2014 | $23,713,000 | +81.8% | 423,452 | +34.4% | 1.06% | +92.4% |
| Q2 2014 | $13,042,000 | -61.8% | 314,952 | -36.2% | 0.55% | -60.7% |
| Q1 2014 | $34,178,000 | +20.0% | 493,400 | +4.4% | 1.41% | +14.5% |
| Q4 2013 | $28,472,000 | +9.9% | 472,400 | +10.8% | 1.23% | -1.5% |
| Q3 2013 | $25,913,000 | +81.9% | 426,200 | +100.4% | 1.25% | +196.2% |
| Q2 2013 | $14,247,000 | – | 212,700 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
| Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
| Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
| Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
| HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
| PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
| NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
| PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
| Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |